New Century Logistics Stock (NASDAQ: NCEW)

Latest news for New Century Logistics (NASDAQ:NCEW) Stock

New Century Logistics (BVI) Ltd is a well-established freight forwarding service provider based in Hong Kong. The company provides air and ocean export and import freight forwarding services ranging from the sale of cargo space, cargo pick up, off-airport air cargo security screening, palletization, preparation of shipping documentation, and arrangement of customs clearance to cargo handling at ports. It provides a full range of global logistics services by providing to its customers with a robust international network that strategically supports the movement of its customers' goods.

New Century Logistics (BVI) Ltd

On Wednesday, Jabil Inc&nbsp;(NYSE:&nbsp;JBL) reported first-quarter revenue of $6.99 billion, down by 16.6% year-on-year, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42550964/jabil-posts-strong-first-quarter-results" rel="noreferrer noopener">analyst consensus estimate&nbsp;of $6.61 billion</a>.&nbsp;
The print manufacturing company&#8217;s adjusted EPS of $2.00 beat the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">analyst consensus estimate of $1.88</a>. The stock price gained after the print.
Also Read: <a target="_blank" href="https://www.benzinga.com/media/24/12/42550951/salesforce-doubles-ai-hiring-goal-to-add-2k-sales-roles" rel="noreferrer noopener">Salesforce Doubles AI Hiring Goal, To Add 2K Sales Roles</a>
Segments: Regulated Industries <a target="_blank" href="https://investors.jabil.com/financials/quarterly-results/default.aspx" rel="noreferrer noopener">revenue declined&nbsp;by</a> 7% Y/Y, Intelligent Infrastructure revenue grew by&nbsp;5% Y/Y, and Connected Living &amp; Digital Commerce revenue decreased by 46% Y/Y.
As of November 30, 2024, the company held $2.06 billion in cash and equivalents. Operating cash flow for the quarter totaled $312 million, with an adjusted free cash flow of $226 million.
CEO Mike Dastoor attributed the quarterly performance to incremental strength in the company&#8217;s Cloud, Data Center Infrastructure, and Digital Commerce end-markets.
Q2 Outlook: Jabil expects first-quarter revenue of $6.1 billion – $6.7 billion (<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">consensus: $6.27 billion</a>) and adjusted EPS to $1.60 – $2.00 (consensus: $1.79).
FY25 guidance: The company expects revenue of $27.3 billion (<a target="_blank" href="https://www.benzinga.com/news/earnings/24/09/41045374/jabils-q4-earnings-beat-1b-buyback-fy25-guidance-and-more" rel="noreferrer noopener">prior $27.0 billion</a>) versus consensus of $27.03 billion and adjusted EPS of $8.75 (prior $8.65) versus estimate of $8.69.
Jabil&nbsp;stock gained 5% year-to-date. In November, on CNBC&#8217;s &#8220;Mad Money Lightning Round,&#8221; Jim Cramer <a target="_blank" href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41847971/jim-cramer-this-tech-stock-is-a-buy-sofi-technologies-is-good" rel="noreferrer noopener">encouraged investors to</a> buy shares of Jabil, calling it &#8220;a great company.&#8221;
Price Action: JBL stock is up 10.60% at $148.10 premarket at the last check on Wednesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/12/42537434/meta-fined-264-million-over-2018-facebook-data-breach-in-europe" target="_blank" rel="noreferrer noopener">Meta Fined $264 Million By EU Watchdog Over 2018 Facebook Data Breach</a></li>
</ul>
Image via Jabil

Earnings

News

Guidance

Tech

Jabil Q1 Earnings: Revenue And EPS Beat, Cloud and Data Center Growth, Raises Annual Outlook

Wells Fargo analyst Michael Blum downgrades Plains All American (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAA#NASDAQ">PAA</a>) from Overweight to Equal-Weight and lowers the price target from $22 to $20.

Downgrades

Price Target

Analyst Ratings

Wells Fargo Downgrades Plains All American to Equal-Weight, Lowers Price Target to $20

Micron Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) will release earnings for its first quarter, after the <a href="https://www.benzinga.com/quote/MU/earnings">closing bell on Wednesday, Dec. 18.</a>
Analysts expect the Boise, Idaho-based company to report quarterly earnings at $1.77 per share, versus a year-ago loss of 95 cents per share. Micron projects to report quarterly revenue of $8.71 billion, compared to $4.73 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
The company has beaten analyst revenue estimates in six straight quarters and seven of the last 10 quarters overall.
With the recent buzz around Micron, some investors may be eyeing potential gains from the company's dividends too. As of now, Micron offers an annual dividend yield of 0.42%. That&#8217;s a quarterly dividend amount of 11.5 cents per share (46 cents a year).
So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $1,551,460 or around 14,286 shares. For a more modest $100 per month or $1,200 per year, you would need $310,270 or around 2,857 shares.
To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($0.42 in this case). So, $6,000 / $0.42 = 14,286 ($500 per month), and $1,200 / $0.42 = 2,857 shares ($100 per month).
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
How that works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
MU Price Action: Shares of Micron gained 0.3% to close at $108.60 on Tuesday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42531171/top-2-utilities-stocks-that-could-sink-your-portfolio-this-quarter">Top 2 Utilities Stocks That Could Sink Your Portfolio This Quarter</a></li>
</ul>
Image: Shutterstock

Long Ideas

Markets

Trading Ideas

How To Earn $500 A Month From Micron Stock Ahead Of Q1 Earnings

Cantor Fitzgerald analyst Eric Schmidt reiterates Agios Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) from Overweight to Overweight.

Reiteration

AGIO

Cantor Fitzgerald Reiterates Overweight on Agios Pharmaceuticalsto Overweight

Wells Fargo analyst Michael Blum downgrades ONEOK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKE#NYSE">OKE</a>) from Overweight to Equal-Weight and maintains the price target from $107 to $107.

Wells Fargo Downgrades ONEOK to Equal-Weight, Maintains Price Target to $107

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

VOXX

Trading Halt: Halted at 8:55:00 a.m. ET - Trading Halt: Halt News Pending

Wells Fargo analyst Michael Blum downgrades Enterprise Prods Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPD#NYSE">EPD</a>) from Overweight to Equal-Weight and announces $35 price target.

Wells Fargo Downgrades Enterprise Prods Partners to Equal-Weight, Announces $35 Price Target

Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) may be riding high with a <a href="https://www.benzinga.com/quote/AAPL/news">$253.48 stock price</a>, but the iPhone 16 cycle is showing signs of stumbling, according to JPMorgan analyst Samik Chatterjee.
The latest Wave7 Research survey paints a mixed picture, with iPhone market share trailing behind the iPhone 15 and iPhone 14 cycles during the critical October to November period. Despite a seasonally better month, the iPhone 16 cycle's market share clocks in at 66%, down from 69% in 2023 and 70% in 2022.
The likely culprit? There is a lack of buzz around Apple Intelligence, the tech giant's much-touted new feature. Carrier store reps say consumer awareness is still alarmingly low—67% of reps surveyed reported "low" awareness, while just 10% called it "high." So much for artificial intelligence leading a real upgrade cycle.
Read Also: <a href="https://www.benzinga.com/24/12/42545936/samsung-galaxy-s25-ultra-and-s25-leaks-show-off-sleek-curved-design-and-slimmer-bezels-than-apples-iphone-16-pro-max">Samsung Galaxy S25 Ultra And S25+ Leaks Feature Sleek Curved Design And Slimmer Bezels Than Apple&#8217;s iPhone 16 Pro Max</a>
<h3 class="wp-block-heading">Apple Pro Max Powers Ahead, Leaving The Plus In The Dust</h3>
While the overall iPhone 16 cycle may be underwhelming, the high-end iPhone 16 Pro Max is stealing the spotlight, leading sales across all carriers with an impressive 19% share. It's clear that Apple's premium strategy is paying off at the top end of the spectrum, even as the 16 Plus struggles with a mere 7% share.
The Samsung S24 Ultra outshone Apple's iPhone 16 Pro/Max in photography chops, with its superior range and resolution earning 50% of the votes. Apple trailed with 30%, barely edging out Google's Pixel 9 Pro/XL at 18%.
<h3 class="wp-block-heading">What's Next For Apple?</h3>
While Apple Intelligence hasn't captured the public imagination yet, Apple's loyal base and robust sales of high-end models suggest the potential for a second wind. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42548075/us-stock-markets-outsized-influence-resurges-as-it-dominates-two-thirds-of-msci-world-indexs-capitalization-mirroring-late-1980s-peak">US Stocks Led By Apple, Nvidia, And Other Tech Giants Dominate Nearly Two-Thirds Of MSCI World Index, Drawing Parallels To 1980s Peak</a></li>
</ul>
Image: Courtesy of Apple

AAPL

Apple's iPhone 16 Stumbles On 'Intelligence' Awareness, But Pro Max Shines Bright: Analyst

Cantor Fitzgerald analyst Deepak Mathivanan reiterates Uber Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) with a Overweight and maintains $90 price target.

UBER

Cantor Fitzgerald Reiterates Overweight on Uber Technologies, Maintains $90 Price Target

Samir R. Patel, M.D., appointed as Chief Executive Officer
Abizer Gaslightwala appointed to Board of Directors
BOSTON and LONDON, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKTX#NASDAQ">AKTX</a>) today announced the appointment of Samir R. Patel, M.D., as Chief Executive Officer, effective December 16, 2024. Dr. Patel has served as interim Chief Executive Officer since May 2024. Additionally, the Company announced it has appointed Abizer Gaslightwala to its Board of Directors, effective December 16, 2024. Michael Grissinger, a member of the Board of Directors, provided notice of his resignation on December 16, 2024.

Management

AKTX

Akari Therapeutics Announces Samir R. Patel, M.D., Appointed As CEO, Effective December 16, 2024

Frequency Electronics, Inc. (&quot;FEI&quot; or the &quot;Company&quot;) (NASDAQ-FEIM), a leading provider of precision timing and frequency control products, is pleased to announce that it has been awarded several significant contracts to supply specialized precision quartz oscillators, synthesizers, and receivers for aerospace programs. The total value of these contracts is approximately $11 million, with deliveries scheduled through 2026. These contracts highlight FEI&#39;s continued leadership in the high-performance frequency control industry and underscore the company&#39;s long-standing commitment to supporting critical aerospace and defense programs. The quartz oscillators will play a key role in navigation and timing systems, contributing to the overall success of the missions by ensuring highly accurate performance under extreme conditions. FEI&#39;s quartz oscillators are renowned for their reliability, stability, and precision&mdash;critical attributes for applications in space and defense. These contracts reflect FEI&#39;s expertise in providing tailored, mission-critical components that meet the rigorous demands of the aerospace and defense sectors.

Contracts

FEIM

Frequency Electronics Awarded ~$11M In Contracts For Quartz Oscillators, Synthesizers, And Receivers For Aerospace Programs

WIIM

Toro shares are trading lower after the company reported worse-than-expected Q4 earnings and sales.

GSAT

Hawk Networks Collaborates With Globalstar To Simplify Access To Licensed Spectrum.

Health Care

General

Tempus Signs Agreements For In-Network Provider Status With  Blue Cross Blue Shield Of Illinois, Blue Shield Of California And Avalon Healthcare Solutions

Cantor Fitzgerald analyst Andres Sheppard maintains Archer Aviation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) with a Overweight and raises the price target from $10 to $13.

ACHR

Cantor Fitzgerald Maintains Overweight on Archer Aviation, Raises Price Target to $13

- Randomized Phase 2 study initiated evaluating the combination of casdozokitug, toripalimab and bevacizumab in patients with liver cancer -
REDWOOD CITY, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc.&nbsp;(("Coherus, NASDAQ:<a href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) today announced that an abstract highlighting final clinical and biomarker data from its Phase 2 clinical trial evaluating casdozokitug (casdozo), a selective and potent IL-27-antagonistic antibody, in combination with atezolizumab (atezo) and bevacizumab (bev) in treatment naïve patients with unresectable locally advanced or metastatic hepatocellular carcinoma (HCC), has been selected for a poster presentation at the upcoming 2025 ASCO GI Annual Meeting, being held January 23-25, 2025, in San Fransisco, CA.

Biotech

CHRS

Coherus To Present Randomized Phase 2 Study Evaluating The Combination Of Casdozokitug, Toripalimab And Bevacizumab In Patients With Liver Cancer

OKLO

Oklo shares are trading higher after the company and Switch signed a non-binding Master Power Agreement to deploy 12 gigawatts of Oklo Aurora powerhouse projects through 2044.

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2024/12/17/final-trades-baker-hughes-raymond-james-wabtec-and-boeing.html">Halftime Report Final Trades</a>,&#8221; Joshua Brown of Ritholtz Wealth Management said Baker Hughes Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>) is <a href="https://www.benzinga.com/quote/BKR/earnings">going higher</a>.
Baker Hughes will announce the results of the fourth quarter on Thursday, Jan. 30, 2025. Analysts expect the company to report quarterly earnings at 63 cents per share on revenue of $7.09 billion.
Brian Belski of BMO Capital Markets named Raymond James Financial, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RJF#NYSE">RJF</a>) as his final trade.
On Dec. 12, Wells Fargo analyst Michael Brown downgraded Raymond James Finl from Overweight to Equal-Weight and raised the price target from $152 to $169.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a> 
Karen Firestone of Aureus Asset Management picked Westinghouse Air Brake Technologies Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAB#NYSE">WAB</a>).
On Nov. 13, Keybanc analyst Steve Barger maintained Westinghouse Air Brake with an Overweight rating and raised the price target from $200 to $220.
Stephanie Link of Hightower picked The Boeing Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>), saying it's a great set up for 2025.
Boeing has restarted production of all airplane programs previously halted by a machinists' strike in the Pacific Northwest. The company confirmed that it resumed production of its popular 737 MAX jetliner earlier in December, following the conclusion of a seven-week strike involving 33,000 factory workers, <a href="https://www.benzinga.com/news/24/12/42546755/boeing-resumes-production-of-767-and-777-aircraft-after-seven-weeks-long-machinists-strike-comes-to-an-end">Reuters reported on Wednesday.</a>
Price Action:
<ul>
<li>Baker Hughes shares fell by 0.9% to close at $41.41 on Tuesday.</li>
<li>Raymond James Financial shares fell by 1.6% to settle at $157.90 during Tuesday's session.</li>
<li>Westinghouse Air Brake Technologies shares fell 2% to close at $198.19 during Tuesday's session.</li>
<li>Boeing shares slipped by 0.1% to close at $173.03 on Tuesday.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42531171/top-2-utilities-stocks-that-could-sink-your-portfolio-this-quarter">Top 2 Utilities Stocks That Could Sink Your Portfolio This Quarter</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Media

Boeing, Baker Hughes, Wabtec And A Financial Stock On CNBC's 'Final Trades'

Results published in two articles in Brain Stimulation
LivaNova PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIVN#NASDAQ">LIVN</a>), a market-leading medical technology company, today announced that the journal Brain Stimulation has published two pivotal articles chronicling the unipolar cohort data set for the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT03887715&amp;esheet=54168318&amp;newsitemid=20241217812430&amp;lan=en-US&amp;anchor=RECOVER+clinical+study&amp;index=1&amp;md5=83000a41de4918b809d5e6c5c5d2f567">RECOVER clinical study</a>. The researchers evaluated the safety and efficacy of LivaNova's VNS Therapy&#x2122; System and its effectiveness on quality of life and daily function in this population of patients with treatment-resistant unipolar depression. Overall, the articles concluded that active VNS Therapy, as compared with a no-stimulation control (or sham VNS Therapy), safely and effectively demonstrated clinically meaningful therapeutic effects on depressive symptoms and positive effects on quality of life and daily function. These findings support the use of VNS Therapy to deliver vagus nerve stimulation (VNS) in treatment-resistant depression (TRD) patients.
A total of 493 adults with at least four documented unsuccessful attempts with antidepressant treatments participated in the unipolar cohort of the RECOVER study. At baseline, unipolar patients in the study failed more than 13 antidepressant treatments (on average) – this included, for the majority, one or more interventional therapies (e.g., transcranial magnetic stimulation, electroconvulsive therapy, or esketamine). While the RECOVER study did not meet the primary endpoint due to a strong and unforeseen response in the sham group, the active treatment arm demonstrated statistically significant and clinically meaningful improvement from the treatment arm's baseline. Further, the RECOVER study demonstrated statistically significant and clinically meaningful benefits in select secondary endpoints for this cohort. Based upon these findings and the positive effects for those who received VNS Therapy, the Company conducted additional in-depth data analyses and plans to submit three additional critical manuscripts to report on the outcomes.

LIVN

LivaNova Announces RECOVER Clinical Study Shows Meaningful Benefits Of It's VNS Therapy System In Select Secondary Endpoints For Unipolar Patients With Treatment-Resistant Depression; Results Published In Two Articles In 'Brain Stimulation'

New Century Logistics (NCEW) announces the pricing of its initial public offering of 1.5M ordinary shares at a public offering price of $4.00 per s...

New Century Logistics prices 1.5M shares at $4.00 in initial public offering

New Century Logistics (NCEW) announces the pricing of its initial public offering of 1,500,000 ordinary shares at a public offering price of $4.00 ...

New Century Logistics prices 1.5 shares at $4.00 in inital public offering

NCEW

New Century Logistics

NEW CENTURY LOGISTICS (BVI) LIMITED (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCEW#NASDAQ">NCEW</a>) IPO will take place December, 18 on the NASDAQ exchange under the ticker NCEW.
The company is offering shares at an expected price between $4.00 and $5.00 per share with an insider lock-up period of 180 days ending on June 16, 2025.
See also: <a href="https://www.benzinga.com/calendars/ipos">Benzinga IPO Calendar</a>
<h3>About NEW CENTURY LOGISTICS (BVI) LIMITED</h3>
New Century Logistics is a well-established international freight forwarding and logistics service provider founded and based in Hong Kong. Our history can be traced back to 2002 when NCL (HK) was incorporated and which commenced its operation as a freight forwarder in 2004
See also: <a href="https://www.benzinga.com/short-interest">Benzinga's Most Shorted Stocks</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

New Century Logistics

News

Latest news for New Century Logistics (NASDAQ:NCEW) Stock

Tuesday, December 17, 2024

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga